The Oak Centre for Children and Young People

£8.5 million

donated by The Oak Foundation to OCCYP in 2010

For 12 years, The Oak Foundation has supported The Royal Marsden Cancer Charity, donating £14.8 million to fund the hospital’s state-of-the-art facilities, leading-edge equipment and pioneering research.

So, where has the money been spent? In 2004, Oak funded a new PET/CT scanner to help diagnose cancer earlier, target tumours more effectively and better assess treatments. In the same year, it funded the Oak Foundation Drug Development Unit (DDU), one of the world’s largest facilities dedicated to testing new cancer therapies.

The impact of the DDU has touched thousands of patients. Among them was Phil Malling, who was diagnosed with bowel cancer. He volunteered for a series of clinical drug trials that have changed his life.

“The Royal Marsden has given me hope for the future,” Phil said. “I was told my bowel cancer was untreatable before coming here, but I am now on my 42nd cycle on a drug trial and living a relatively normal life. Without the DDU and the experts there, I would not be here now, enjoying life and making the most of every day.”

In 2010, Oak contributed £8.5 million towards the Oak Centre for Children and Young People (OCCYP). The centre is designed around the needs of our young patients and has outstanding modern facilities. Oak has also donated £3.3 million towards The Royal Marsden’s paediatric drug development programme since 2005.

Dr Lynley Marshall, Consultant in Paediatric and Adolescent Oncology Drug Development, said: “Not only can young patients be offered early access to clinical trials of novel, promising anti-cancer drugs and personalised medicine developed onsite, the OCCYP also offers hope to patients and their families.”

Antonia Dalmahoy, Managing Director of The Royal Marsden Cancer Charity, said: “Our relationship with Oak is very special to us. The impact of their philanthropy at The  Royal Marsden can be seen everywhere and, with their support, patients of all ages can access the best research, equipment and facilities.